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Abstract 
Background+
Accurate differentiation of bipolar and unipolar depression is a key clinical 
challenge. A biological measure that could differentiate bipolar and unipolar 
depression might supplement clinical assessment. Magnetic Resonance 
Spectroscopy measurements of total glutamate and glutamine (Glx) in anterior 
cingulate cortex are one potential measure. The objective of this study was to 
assess the potential performance of this measure. 
Methods+
Meta-analysis of data from eleven studies where anterior cingulate Glx of 
depressed patients has been compared to that of healthy controls was 
performed. Effect sizes for bipolar and unipolar depression were calculated as 
Standardised Mean Differences. The best estimate of test classification 
performance on the basis of observed effects was calculated. 
Results+
People with unipolar depression had on average lower levels of Glx than healthy 
controls (effect size -1.05; 95% CI -.58 to -1.53). People with bipolar depression 
tended towards higher Glx than healthy controls (effect size 0.40; 95% CI -.04 to 
0.85). This yielded a difference in Glx between unipolar and bipolar depression of 
effect size 1.46 (95% CI 0.80 to 2.11). Based on this difference, a test 
differentiating bipolar from unipolar depression by whether Glx was higher or 
lower than the average in healthy population would have sensitivity .66 and 
specificity .85. 
Limitations+
There is an absence of studies directly comparing unipolar and bipolar 
depressed patients. 
Conclusions+
On available data, measurement of anterior cingulate Glx is a promising potential 
tool for differentiation of bipolar and unipolar depression. This potential effect 
requires direct validation within mixed clinical cohorts. 
Keywords:+Bipolar+depression,+Magnetic+resonance+spectroscopy,+glutamate,+glutamine,+major+depressive+
disorder++ +
  
Introduction 
Accurate identification of bipolar depression remains a major clinical challenge. 
Typically within bipolar disorder, episodes of depression predominate (Judd et 
al., 2003) and in practice many people with bipolar disorder are initially 
diagnosed and treated as unipolar depression (Hantouche et al., 1998 Hirschfeld 
et al., 2003; Smith et al., 2011). The adverse impact of missed diagnosis of 
bipolar disorder has been known for some time (Dunner, 2003). As growing 
evidence indicates that the optimal management of bipolar and unipolar 
depression differs substantially, the critical importance of early identification of 
bipolar depression becomes even clearer (Goodwin, 2012). 
Episodes of major depression within bipolar disorder and unipolar depressive 
disorder show substantial overlap in presentation. Although some characteristics 
are more commonly associated with bipolar disorder, at present such differences 
remain probabilistic rather than being sufficient to guide differences in 
management by themselves (Mitchell et al., 2008). A number of screening tools 
have been developed in recent years to identify people most likely to receive a 
diagnosis of bipolar disorder (Angst et al., 2005; Ghaemi et al., 2005; Hirschfeld 
et al., 2000 ). However, even with expert clinical assessment, people who will go 
on to develop bipolar disorder but have as yet only experienced depressive 
episodes cannot be identified accurately. 
A biological measure that could differentiate bipolar and unipolar depression 
would therefore be of interest as a supplement to clinical assessment. It might be 
of benefit clinically where historical information is unclear or contradictory, or as a 
potential research tool in future studies, for example identifying those at highest 
risk of conversion to bipolar disorder. Glutamate neurotransmission has been of 
increasing interest in mood disorders including bipolar disorder in recent years 
(Sanacora et al., 2008). The imaging technique Magnetic Resonance 
Spectroscopy (MRS) allows for safe, non-invasive measurement of glutamate 
levels in the brain. In practice differentiation of glutamate from the related 
chemical glutamine is challenging with MRS, so the total combined glutamate 
and glutamine (Glx) level is often reported. 
There is now a growing literature of glutamate MRS studies in mood disorders. 
An emerging pattern points to decreased Glx in unipolar depression and 
increased Glx in bipolar depression in some brain regions (Gigante et al., 2012; 
Yüksel and Öngür, 2010 ). Here we address quantitatively the question of 
whether this difference might be of diagnostic use, focusing on measures of Glx 
in anterior cingulate cortex, a region known to play an important role in bipolar 
disorder (Strakowski et al., 2012). We employ meta-analysis to quantify the 
differences described by the literature to date, and the extent of uncertainty 
around that estimate, and model the diagnostic test performance that would 
result from this difference. 
  
Materials and Methods 
Search+strategy+
Studies comparing levels of Glx between people with a current episode of major 
depression and a control population were sought. Studies where the MRS voxel 
encompassed medial prefrontal cortex including pregenual anterior cingulate 
cortex were included. Studies published to January 2014 were identified by 
searches of MEDLINE and EMBASE, reference lists of identified articles, and 
from personal reference collections. 
Data+extraction+
Levels of Glx (mean and standard deviation) within anterior cingulate cortex for 
currently depressed participants and the control population were extracted. 
Levels reported either relative to creatine or tissue water were accepted. Where 
suitable data was not reported in the published article or could not be imputed 
from available data, further details were sought from the authors. No studies 
were excluded on the basis of spectral quality, but it was typical for studies to 
restrict their analysis to metabolite estimates meeting a set criterion e.g. Cramér-
Rao SD less than 20% (Chen et al., 2014). 
Meta-analysis was performed using a random effects model (DerSimonian-
Laird), and standardised mean differences (Hedges’ adjusted g) employed for 
measures of effect given differences in technical approaches employed (Table 
1). Statistical heterogeneity between studies was assessed by I2 (Higgins et al., 
2003) which expresses the percentage of total variation across studies that is 
due to heterogeneity rather than chance. Meta-regression for effect of diagnosis 
was performed using a mixed-effects model (Viechtbauer, 2010). Differences in 
Glx levels between unipolar and bipolar depression were calculated by adjusted 
indirect comparison (Glenny et al., 2005). 
Table+1+near+here+
A receiver operating curve (ROC) was calculated for the ability to differentiate 
bipolar from unipolar depression by Glx level given normal distributions for each 
disorder separated by the estimates of effect size established by meta-analysis. 
ROCs display the sensitivity and specificity of a test across all criterion levels that 
could be chosen. Total area under the curve (AUC) was calculated. An AUC of 
1.0 indicates perfect performance, whereas an AUC of 0.5 indicates performance 
no better than chance alone. Statistical analyses were performed using R 
(version 3.0.2) with the meta (version 3.1-2) and metafor (version 1.9-2) 
packages (Schwarzer, 2013; Viechtbauer, 2010). 95% Confidence Intervals (CI) 
for estimates are presented where available. 
Results 
Eleven studies were identified as suitable for inclusion (Table 1). In these studies 
a total of 421 participants provided data. No studies were identified that had 
compared unipolar and bipolar depression directly. Seven studies compared 
anterior cingulate cortical Glx during episodes of unipolar depression to that of 
healthy controls. (In one study, one of 19 depressed participants had a diagnosis 
of bipolar disorder; (Auer et al., 2000)). Four studies compared Glx between 
bipolar depression and healthy controls. Some additional studies of anterior 
cingulate glutamate spectroscopy were identified but could not be included as 
glutamate levels were reported but Glx was not reported and data could not be 
obtained from the authors. 
Figure+1+near+here+
Glx differed significantly between the diagnostic groups (p<.0001). People with 
unipolar depression had on average lower levels of Glx than healthy controls. An 
effect size of -1.05 (95% CI -.58 to -1.53) was found for this difference. There 
was moderately high statistical heterogeneity in estimates between studies (I2 
64%). People with bipolar depression tended towards higher Glx than healthy 
controls. An effect size of 0.40 (95% CI -0.04 to 0.85) was found for this 
observation. The result was more consistent across studies, with lower statistical 
heterogeneity (I2 44%). The best estimate of the difference in Glx between 
unipolar and bipolar depression was of effect size 1.46 (95% CI 0.80 to 2.11). 
The ROC analysis (Figure 1B) indicated that overall predicted test performance 
was good with AUC 0.85 (95% CI 0.72 to 0.93). The expected performance for 
differentiating bipolar from unipolar depression by whether Glx was higher or 
lower than the average in healthy population was found to be sensitivity .66 and 
specificity .85. 
  
Discussion 
Here we have addressed quantitatively the question of whether levels of Glx in 
anterior cingulate cortex measured using MRS have the potential to differentiate 
bipolar from unipolar depression. The published literature to date indicates that 
medium to large effect sizes are observed comparing either unipolar or bipolar 
depression to healthy controls. However, since the effects are in opposite 
directions, a very large effect size (1.46) is estimated for the difference between 
bipolar and unipolar depression. 
The ROC expected performance of a test based on this measure has an AUC 
greater than some recent clinical measures, for example differentiation based on 
clinical features alone (Mitchell et al., 2008) has AUC .63 when employed in 
practice (Mitchell et al., 2011). The test would be expected to have similar 
performance to that reported by some clinical screening tools such as Bipolar 
Spectrum Diagnostic Scale (BSDS) (Ghaemi et al., 2005), Hypomania Checklist 
(HCL-32) (Angst et al., 2005) and the Mood Disorder Questionnaire (MDQ) 
(Hirschfeld et al., 2000). A recent application of two of these screening tools in 
primary care estimated AUC for HCL-32 of .81, and for BSDS .71 (Smith et al., 
2011). 
The neurobiological interpretation of the difference in Glx levels remains 
uncertain, since differences in Glx could be explained be alterations in either 
glutamate or glutamine levels. As technical advances begin to allow accurate 
differentiation of glutamate from glutamine, changes in glutamine:glutamate ratio 
appear to be more closely related to brain glutamatergic function. It is interesting 
that during unipolar depression some studies have reported reduced glutamine 
(Walter et al., 2009) whereas in episodes of mania an increased ratio has been 
observed (Ongür et al., 2008). 
The differences in anterior cingulate Glx reported may reflect altered 
glutamatergic signalling or neuronal function in that region. In keeping with this, 
recent functional imaging data points to differences between bipolar and unipolar 
depressed individuals in regions including anterior cingulate (Bertocci et al., 
2012; Mourão-Miranda et al., 2012). It is of course possible that similar Glx 
differences by diagnosis may also be demonstrable in other brain regions, since 
a similar trend towards Glx reductions in unipolar depression and elevations in 
bipolar disorder has been noted in other grey matter regions (Yüksel and Öngür, 
2010). 
The origins of the heterogeneity in Glx effect observed remain unclear. Some 
studies have suggested the greatest alterations in MRS measures are associated 
with particular clinical characteristics such as anhedonia (Walter et al., 2009), or 
may emerge with disease progression over time (Portella et al., 2011). However, 
against this, one of the greatest magnitude effects in unipolar depression seen 
was in a young population (Mirza et al., 2004). 
Medication is a logical potential confounding factor on any biological measure. 
While included studies vary by mediation status, it seems unlikely to explain the 
overall effect found here. It has proven challenging to demonstrate an direct 
effect of common medications such as the SSRIs on this measure (Taylor et al., 
2010), and even for more novel glutamatergic agents such as ketamine, results 
are mixed (Stone et al., 2012; Taylor et al., 2011). It has also been possible to 
replicate the finding in unmedicated samples (Hasler et al., 2007). It has been 
reported that pretreatment spectroscopic measures may predict in part ketamine 
treatment response, specifically that a surrogate of glutamine concentration may 
do so (Salvadore et al., 2012). Given that ketamine has promising treatment 
effects in both bipolar and unipolar depression (Berman et al., 2000; Zarate et al., 
2012), it is therefore interesting to note that the differences in Glx do not rule out 
underlying similarities in e.g. glutaminergic function across disorders. 
Small differences in voxel positioning between centres could increase 
heterogeneity if the Glx effect was highly localised. However, if the effect is more 
widespread as noted above this would decrease the magnitude of this factor. 
Interestingly one study that included both more dorsal and more ventral voxel 
positions reported a similar effect of diagnosis on Glx in both, whereas an effect 
on GABA levels was more localised (Hasler et al., 2007). 
In usual clinical practice, no biological measure is likely to replace high quality 
clinical assessment. However if differing concentrations of Glx reflect core 
differences in neurobiology between the disorders, they might predate the first 
hypomanic or manic episode. Anterior cingulate Glx therefore warrants study in 
groups at high risk of progression to bipolar disorder as a possible adjunct to 
clinical assessment. As poor response to treatment of depression is associated 
with elevated risk of conversion to bipolar disorder (Li et al., 2012), future studies 
could investigate whether higher Glx levels were predictive of this. 
On available data, measurement of anterior cingulate Glx by MRS is a promising 
potential tool for differentiation of bipolar and unipolar depression. This potential 
effect requires direct validation within mixed clinical cohorts. Future studies could 
investigate in particular whether this imaging measure adds discriminatory ability 
to clinical measures alone or as part of a multi-modal imaging classifier. 
  
Legends 
Figure+1+
A) Forest plot of standardised mean differences (SMD) with 95% confidence 
intervals of differences in Glx concentration in anterior cingulate cortex 
between currently depressed individuals and healthy controls. Subgroup 
estimates presented for those with unipolar and bipolar depression. Data 
from Portella et al. 2011 presented separately for those with first 
presentation with depression (f) and chronic course (ch). 
B) Receiver operating curve for differentiation of bipolar and unipolar 
depression by measurement of Glx levels in anterior cingulate cortex. Best 
estimate of test performance shown (solid line) with 95% confidence 
intervals (dashed lines) and the line of no effect (dotted oblique line). 
Estimated performance using mean of healthy control Glx levels as criterion 
is shown (dot). 
Table+1+
Characteristics of included studies. 
  

Table 1 
Study Participants 
Diagnostic 
criteria 
Mean 
age of 
patients 
(yr) 
Symptom 
severity 
Medication 
status 
MRS 
acquisition 
Magnet 
field 
strength 
(T) Notes 
Dager 
2004 
32 bipolar I or 
bipolar II, 
predominantly 
depressed or 
mixed state vs 26 
matched controls 
DSM-IV 30.3 HAMD (17 
item) 17.7 
+- 8.6 
Medication 
free 
PEPSI 1.5 left 
anterior 
cingulate 
data 
included 
Frye 
2007 
26 bipolar I or 
bipolar II 
depression vs 12 
DSM-IV 35.6 MADRS 
27.5 +- 6.2 
5 receiving 
lithium 
PRESS 1.5 
healthy controls 
Patel 
2008 
28 bipolar I, 
currently 
depressed vs 10 
controls 
K-SADS 15.5 CDRS-R 
63.2 +- 
12.6 
Medication 
free at time of 
scan 
PRESS 1.5 
Xu 2013 12 bipolar 
depressed vs 20 
controls 
DSM-IV 37 HDRS 19 ± 
3 
Medication 
free 
2D MRSI 3 data from 
12 manic 
patients 
not used 
Auer 
2000 
19 depressed 
(one bipolar) vs 
18 controls 
ICD-10 50.2 14 severe, 
5 medium 
by ICD-10 
severity 
criteria 
7 medication 
free or 
sedatives only 
PRESS 1.5 
Pfleiderer 17 patients vs 17 DSM-IV 61 MADRS All but one STEAM 1.5 
2003 controls 37.7 +-8.8 patient 
medication 
free 
Mirza 
2004 
13 MDD patients 
vs 13 controls 
DSM-IV 15.54 CDRS-R 
59.08 +-8.8 
Psychotropic 
naive 
PRESS 1.5 
Hasler 
2007 
20 MDD patients 
vs 20 controls 
DSM-IV 34 MADRS 27 
+- 4.3 
Unmedicated PRESS-
based J-
editing 
3 
Horn 
2010 
22 MDD patients 
vs 22 controls 
ICD-10 37.62 HAMD (21 
item) 17.17 
+- 4.74 
All patients 
medicated 
PRESS 3 
Portella 
2011 
10 first episode 
and 19 chronic 
MDD patients vs 
15 controls 
DSM-IV-
TR 
44,5 (first 
episode) 
50.96 
(chronic) 
HDRS 13 
+_ 9.7 (first 
episode) 
21.39 +- 
All patients 
medicated 
PRESS 3 Data from 
16 patients 
in 
remission 
4.5 
(chronic) 
not used 
Chen 
2014 
15 MDD patients 
vs 15 controls 
DSM-IV 27.87 HDRS 
23.33 ± 
4.36 
No 
medication for 
at least two 
weeks 
PRESS 1.5 
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